Skip to main content

Sources last read

FDA report analysis · eight GLP-1 brands

Why has my GLP-1 stopped working?

The FDA reports cannot explain why your treatment seems to have stopped working. The term drug ineffective accounts for 6.6% of Zepbound reports, the largest share among these 8 brands. All 8 include the term among their most reported events.

Source for this answer

Source: FDA side-effect reports, read 2026-08-17

Source: FDA side-effect reports, read 2026-08-17

That is not a treatment failure rate. The report total does not count everyone who used the drug, including people whose treatment worked. A share of reports only tells you what the submitted reports were about.

The term does not give a reason. Reports can come from patients, healthcare professionals or companies. This summary does not show whether a report concerned weight, blood sugar, a device problem or something else.

Across FDA reports

Products in the table

8

Carrying the term

8

Known only as a ceiling

0

Highest — Zepbound

6.6%

Which products have FDA reports for drug ineffective

One FDA adverse-event term compared across eight brands. Each percentage uses that product’s own report total, so the columns should not be pooled.

◆ drug ineffective — share of each product’s own reportsShare of that product’s reports
8Exact values — 8 rows in the data table
drug ineffective — share of each product’s own reports
ProductShare of that product’s reports
Zepboundtirzepatide6.6% of Zepbound reports
Saxendaliraglutide5.3% of Saxenda reports
Trulicitydulaglutide4.2% of Trulicity reports
Wegovysemaglutide3.6% of Wegovy reports
Victozaliraglutide2.9% of Victoza reports
Mounjarotirzepatide2.6% of Mounjaro reports
Ozempicsemaglutide2.3% of Ozempic reports
Rybelsussemaglutide2.2% of Rybelsus reports

Hatched, open-ended bars are ceilings rather than measurements. Read from FDA on 2026-08-17.

A dashed row is not a zero. The snapshot keeps each product’s 25 most-reported terms, so a term missing from that list was either never reported or reported and ranked 26th. All this page can prove is that it sits at or below the 25th, and that is what the row says.

Every share above is a share of that product’s own reports. It is never a share of the people who took it, because nobody knows how many that is. Two products can differ here for reasons that have nothing to do with either drug.

What FDA reports show across eight brands

Zepbound sits highest and Rybelsus lowest, and every brand in between carries the term. The spread runs about threefold, which is narrow next to the spreads on other terms.

The term appears across all eight brands, but that does not show that the reports share a cause. A count of the same words cannot separate treatment response, product use and other circumstances.

Weight increased is also shown. It appears among the stored terms for six of the eight brands. Those reports name weight gain; they do not tell us why someone was taking the drug or why their weight changed.

Another event in the same reports

Weight decreased records a report of weight loss. The term alone does not tell us whether that loss was intended, welcome or related to treatment.

◆ weight decreased — share of each product’s own reportsShare of that product’s reports
8Exact values — 8 rows in the data table
weight decreased — share of each product’s own reports
ProductShare of that product’s reports
Ozempicsemaglutide6.3% of Ozempic reports
Victozaliraglutide4.8% of Victoza reports
Rybelsussemaglutide4.7% of Rybelsus reports
Trulicitydulaglutide3.9% of Trulicity reports
Mounjarotirzepatide2.2% of Mounjaro reports
Wegovysemaglutidebelow 2.0% of Wegovy reports
Saxendaliraglutidebelow 1.9% of Saxenda reports
Zepboundtirzepatidebelow 1.9% of Zepbound reports

The same eight products, the same snapshot, a different term. Read from FDA on 2026-08-17.

What could make this number move without the drug changing

This snapshot cannot identify the cause of the pattern. Access problems, treatment use and expectations are possible questions to investigate, not findings established by these totals.

The saved summary does not break these reports down by dose or treatment stage. It cannot tell whether someone was starting treatment, taking a maintenance dose or changing products.

FDA report shares cannot tell whether a drug stopped working for one person. A clinician who can review your dose, timing and health history can answer that question more safely.

What the labels say about it

Adverse-reaction tables do not measure whether treatment met its goal. Clinical-study results are the place to look for the outcomes measured in a defined group of patients.

Labels and trial papers may report weight change, blood sugar outcomes or the share of participants who reached a stated goal. The result depends on the product, study population and follow-up period. There is no single failure rate that applies to every use.

This section summarizes reports people filed. The label guides show what the FDA-approved prescribing information lists. The two answer different questions: what was reported after use, and what was observed in studies.

What this page does and does not establish

The reports show that an event was named. They do not show how often treatment fails.

What each claim is supported by in the report data
The claimWhat the evidence shows
People file reports saying these drugs did not workEstablished. Every one of the eight brands carries the term among its 25 most-reported events. The table shows each product’s own count and share.
One brand fails more often than anotherNot established. The number of people treated is not available here. Differences in reporting may affect each share.
A share here is the chance it will not work for youNot established. The reports are not a sample of everyone treated, so they cannot give your chance of an outcome.
Weight gain gets reported on drugs taken to lose weightEstablished for the brands whose stored terms include it. For the rest, all that can be said is that it sits below their 25th term.

Common questions

Does this mean the drug stops working over time?

No. This snapshot has no time axis inside a person. It records that a report was filed, not how many months of treatment came before it.

Tolerance over time is a real question and it needs a trial that follows the same people, not a report count.

Why would somebody report weight gain on a weight-loss drug?

The reports do not explain why the weight gain happened. They only show that the term appeared among the 25 most reported events for six of the eight brands.

Is a bigger number worse?

Not on its own. A product with more reports of everything will tend to have more reports of this too. That is why the table shows shares rather than counts.

Even then, two products can have different report shares simply because one is older, used more often or discussed more.

Where to go next

This page is one question asked of one snapshot. The pages below answer the neighboring ones from the labels and the trials, which is a different kind of evidence.

Every question in this section is listed on the report-stream questions index.

Read this before quoting anything above

These are counts of reports filed with the FDA, not rates among people treated. This data does not count everyone who used the drug, and a report does not establish that the drug caused the event.

  • No count of everyone treated. FAERS counts submitted reports, not everyone who used a drug. Each percentage here divides an event count by the drug’s report total. It describes a share of reports, not a share of people treated or their chance of an event.
  • A report is not proof the drug did it. FDA does not require proof that a drug caused an event before accepting a report. The drug, an illness or another factor may be involved. A report naming both a drug and an event does not establish the cause.
  • A bigger number can just mean a more-prescribed drug. More reports can simply mean that more people use the drug, that it is newer, or that it receives more news and legal attention. Raw report totals do not tell you which drug is safer.
  • The same event can be counted twice. One event can reach FAERS through more than one channel — the patient, the prescriber and the manufacturer can all file. FDA does not guarantee that the public files are de-duplicated.
  • FDA’s own words. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
  • Retrieved 2026-08-17 from https://api.fda.gov/drug/event.json · FDA data last updated 2026-07-30 · license https://open.fda.gov/license/

How everything on this site is sourced →

10primary sources, each with the day we read it — open the documents used on this page